Country: Ingilterra
Lingwa: Ingliż
Sors: MHRA (Medicines & Healthcare Products Regulatory Agency)
Sodium; Chloride; Potassium; Bicarbonate; Macrogol '3350'
Tillotts Pharma UK Ltd
A06AD65
Sodium; Chloride; Potassium; Bicarbonate; Macrogol '3350'
65mmol/1litre ; 53mmol/1litre ; 5.4mmol/1litre ; 17mmol/1litre ; 105gram/1litre
Powder for oral solution
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 01060400; GTIN: 7640129620968
PACKAGE LEAFLET: INFORMATION FOR THE USER VISTAPREP 110g Powder for oral solution. Macrogol 3350, sodium chloride, sodium bicarbonate and potassium chloride. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What VistaPrep is and what it is used for 2. What you need to know before you take VistaPrep 3. How to take VistaPrep 4. Possible side effects 5. How to store VistaPrep 6. Contents of the pack and other information 1. WHAT VISTAPREP IS AND WHAT IT IS USED FOR VistaPrep is a white powder for oral solution with a laxative effect. VistaPrep is used for bowel cleansing in preparation for the examination of the colon (colonosco- py) in adults over 18 years of age. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE VISTAPREP DO NOT TAKE VISTAPREP if you are allergic to macrogol 3350, sodium chloride, sodium bicarbonate, potassium chloride saccharin sodium, orange flavour, lemon-lime flavour, colloidal anhydrous silica or any of the ingredients of this medicine (listed in section 6); if you have a bowel obstruction or suspected bowel obstruction, strictures or perforations in the gastrointestinal area, or if you are at risk of perforations in the gastrointestinal area; if you suffer from problems emptying your stomach or have a severe, highly inflammato- ry form of colitis (colon inflammation) and a severe, abnormally enlarged colon due to this colitis (toxic megacolon); if you have an impaired swallowing and gag reflex, or suffer from general weakness. VistaPrep should not be administered to patients with impaired consciousness and patients pron Aqra d-dokument sħiħ
OBJECT 1 VISTAPREP 110G POWDER FOR ORAL SOLUTION Summary of Product Characteristics Updated 23-Apr-2018 | Tillotts Pharma UK Limited 1. Name of the medicinal product VistaPrep 110g Powder for oral solution. 2. Qualitative and quantitative composition Each sachet contains the following active substances: Macrogol 3350 105.000 g Sodium chloride 2.800 g Sodium bicarbonate 1.430 g Potassium chloride 0.370 g The electrolyte ion content of one sachet after preparation of 1,000 mL solution is equivalent to: Sodium 65 mmol/L Chloride 53 mmol/L Bicarbonate 17 mmol/L Potassium 5 mmol/L For the full list of excipients, see section 6.1. 3. Pharmaceutical form Powder for oral solution. Appearance: white powder. 4. Clinical particulars 4.1 Therapeutic indications VistaPrep is used for bowel cleansing in preparation for colonoscopy. VistaPrep is indicated in adults over 18 years of age. 4.2 Posology and method of administration Posology For complete bowel cleansing, 3 up to a maximum of 4 litres of VistaPrep solution must be taken. 1 sachet corresponds to 1 L solution. _Paediatric population_ VistaPrep should not be used in children because the safety has not been established in this patient group. Method of administration The route of administration is for oral use. The solution is drunk in portions of 200 - 300 mL every 10 minutes until the rectal effluent is clear or 4 litres maximum have been drunk. Administration takes place over a period of about 4 hours, generally on the examination day. The total amount required can also be taken on the evening before, or a part taken on the evening before and the remaining amount on the morning of the examination day. Patients should consume no solid food for 2 to 3 hours prior to administration of VistaPrep until after the examination. Precautions to be taken before handling or administering the medicinal product For instructions on reconstitution of the medicinal product before administration, see section 6.6. For further directions for use see section 6.2 Incompatibilities. 4.3 Cont Aqra d-dokument sħiħ